Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $17.75.

A number of analysts have recently commented on ATRA shares. Canaccord Genuity Group dropped their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday. Finally, Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock.

Atara Biotherapeutics Price Performance

ATRA opened at $8.88 on Friday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The business has a 50-day moving average of $11.69 and a two-hundred day moving average of $9.90. The stock has a market capitalization of $51.15 million, a price-to-earnings ratio of -0.34 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the firm posted ($16.50) earnings per share. Equities research analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares in the last quarter. State Street Corp boosted its holdings in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. FMR LLC grew its stake in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $53,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.